Protocol Ledger

NCT05529316 · Phase II · TERMINATED

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Interventional Phase II clinical trial protocol NCT05529316 sponsored by Agenus in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-12 Enrollment: 150 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05529316
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05529316
Protocol FieldVerified Registry Value
NCT IdentifierNCT05529316
Consolidated Lead SponsorAgenus
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment150 participants (ACTUAL)
Registered Start Date2022-12-12
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05529316
Hospital Research SiteLocationSite Profile
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->
Georgetown University Medical CenterWashington D.C, DCOpen Hospital Dossier ->
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI